{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T07:15:45Z","timestamp":1788419745624,"version":"build-2803163510"},"reference-count":150,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T00:00:00Z","timestamp":1788393600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Lung cancer remains the leading cause of cancer-related mortality worldwide, and despite the transformative impact of immune checkpoint inhibitors (ICIs), primary and acquired resistance, limited efficacy in immune-cold tumors such as extensive-stage small cell lung cancer (ES-SCLC), and the absence of durable responses in a substantial proportion of patients define the unmet need that T cell-redirected therapies aim to address. These strategies engage, engineer, and deliver cytotoxic T cells against tumor cells independently of preexisting immunity, and this review provides a comprehensive overview of the four major modalities under clinical development in lung cancer: bispecific T cell engagers (BiTEs), tumor-infiltrating lymphocyte (TIL) therapy, chimeric antigen receptor T cell (CAR-T) therapy, and T cell receptor-engineered T cell (TCR-T) therapy. Among these, tarlatamab, a DLL3\u00d7CD3 BiTE, has achieved the most advanced clinical validation, receiving traditional FDA approval in November 2025 for second-line ES-SCLC following Phase 3 DeLLphi-304 data demonstrating superior overall survival versus chemotherapy (median 13.6 vs. 8.3 months; HR 0.60). TIL therapy is the leading adoptive cell approach in non-small cell lung cancer (NSCLC), with lifileucel demonstrating a 25.6% ORR in anti-PD-1-resistant disease and a 64.3% ORR when combined with pembrolizumab in ICI-na\u00efve patients, though manufacturing complexity and cost constrain broad access. CAR-T and TCR-T therapies remain in early proof-of-concept phases, limited by the absence of uniformly expressed tumor-restricted surface antigens in NSCLC, MHC class I downregulation, and the sub-1% eligibility rates imposed by HLA restriction in TCR-T programs, while generating important engineering insights around genome editing, armored cytokine payloads, and neoantigen targeting strategies. Shared challenges across all modalities include antigen loss under therapeutic pressure, T cell exhaustion driven by the immunosuppressive lung tumor microenvironment, and the absence of prospectively validated predictive biomarkers for patient selection. Combination strategies pairing T cell-redirected therapies with ICIs, antibody-drug conjugates, and allogeneic or innate immune effectors represent the most promising path toward durable benefit. As the field advances toward Phase 3 trials, biomarker-selected patient populations, and scalable allogeneic manufacturing platforms, T cell-redirected therapy is positioned to extend the survival frontier for patients whose lung cancer has escaped existing treatments.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1917770","type":"journal-article","created":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:43:44Z","timestamp":1788417824000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["T-cell redirecting therapies in lung cancer -\u00a0a comprehensive analysis of clinical trials"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiahe","family":"Zhao","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, John Theurer Cancer Center, Hackensack University Medical Center","place":["Hackensack, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayrton","family":"Bangolo","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, John Theurer Cancer Center, Hackensack University Medical Center","place":["Hackensack, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, John Theurer Cancer Center, Hackensack University Medical Center","place":["Hackensack, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, John Theurer Cancer Center, Hackensack University Medical Center","place":["Hackensack, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Gonzalez-Velez","sequence":"additional","affiliation":[{"name":"Department of Thoracic Oncology and Phase I Therapeutics, John Theurer Cancer Center, Hackensack University Medical Centerr","place":["Hackensack, NJ, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00844-0","article-title":"Lung cancer in patients who have never smoked \u2014 an emerging disease","volume":"21","author":"LoPiccolo","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.05.024","article-title":"Air pollution and lung cancer: a review by International Association for the Study of Lung Cancer Early Detection and Screening Committee","volume":"18","author":"Berg","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non\u2013small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02825","article-title":"Therapy for stage IV non\u2013small cell lung cancer without driver alterations: ASCO living guideline, 2026.3.0","volume":"44","author":"Reuss","year":"2026","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non\u2013small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1366260","article-title":"Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges","volume":"15","author":"Xiang","year":"2024","journal-title":"Front Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/17588359241302021","article-title":"Next-generation immunotherapy: igniting new hope for lung cancer","volume":"16","author":"Li","year":"2024","journal-title":"Ther Adv Med Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12943-023-01926-4","article-title":"Evolving insights into the improvement of adoptive T-cell immunotherapy through PD-1\/PD-L1 blockade in the clinical spectrum of lung cancer","volume":"23","author":"Li","year":"2024","journal-title":"Mol Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1728163","article-title":"Lung cancer immunotherapy in 2025: where we stand and what comes next","volume":"16","author":"Han","year":"2025","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum\u2013etoposide versus platinum\u2013etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"102606","DOI":"10.1016\/j.ctrv.2023.102606","article-title":"Shaping the tumor immune microenvironment of SCLC: mechanisms, and opportunities for immunotherapy","volume":"120","author":"Chen","year":"2023","journal-title":"Cancer Treat Rev"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1038\/s41467-025-56527-0","article-title":"Unlocking the potential of engineered immune cell therapy for solid tumors","volume":"16","author":"Albarr\u00e1n-Fern\u00e1ndez","year":"2025","journal-title":"Nat Commun"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0347-5","article-title":"T cell-engaging therapies - BiTEs and beyond","volume":"17","author":"Goebeler","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0014-x","article-title":"Understanding the tumor immune microenvironment (TIME) for effective therapy","volume":"24","author":"Binnewies","year":"2018","journal-title":"Nat Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-021-02054-3","article-title":"Single-cell RNA sequencing reveals distinct tumor microenvironmental patterns in lung adenocarcinoma","volume":"40","author":"Bischoff","year":"2021","journal-title":"Oncogene"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1674449","DOI":"10.3389\/fimmu.2025.1674449","article-title":"Advancements in extensive-stage small cell lung cancer therapy: from molecular profiling to the advent of precision oncology","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15235706","article-title":"Unraveling the intricacies of CD73\/adenosine signaling: the pulmonary immune and stromal microenvironment in lung cancer","volume":"15","author":"Saig\u00ed","year":"2023","journal-title":"Cancers"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00574-3","article-title":"CD8+ T cell differentiation and dysfunction in cancer","volume":"22","author":"Philip","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2035","article-title":"T cell exhaustion","volume":"12","author":"Wherry","year":"2011","journal-title":"Nat Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-019-0221-9","article-title":"Defining \u2018T cell exhaustion.\u2019","volume":"19","author":"Blank","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12071760","article-title":"MHC class I downregulation in cancer: underlying mechanisms and potential targets for cancer immunotherapy","volume":"12","author":"Cornel","year":"2020","journal-title":"Cancers"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor (CAR) design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2026.2632421","article-title":"Trial watch - bispecific T cell engagers and higher-order multispecific immunotherapeutics","volume":"15","author":"Xue","year":"2026","journal-title":"Oncoimmunology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03125-y","article-title":"T cell engagers: expanding horizons in oncology and beyond","volume":"133","author":"Albayrak","year":"2025","journal-title":"Br J Cancer"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2024.03.027","article-title":"Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy","volume":"14","author":"Qin","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/science.1158545","article-title":"Tumor regression in cancer patients by very low doses of a T cell-engaging antibody","volume":"321","author":"Bargou","year":"2008","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13045-019-0745-2","article-title":"DLL3: an emerging target in small cell lung cancer","volume":"12","author":"Owen","year":"2019","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"302ra136","DOI":"10.1126\/scitranslmed.aac9459","article-title":"A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo","volume":"7","author":"Saunders","year":"2015","journal-title":"Sci Transl Med"},{"key":"B33","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/S1470-2045(16)30565-4","article-title":"Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study","volume":"18","author":"Rudin","year":"2017","journal-title":"Lancet Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-2845","article-title":"AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer","volume":"27","author":"Giffin","year":"2021","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study","volume":"16","author":"Blackhall","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3390\/antib15010004","article-title":"Updates on antibody drug conjugates and bispecific T-cell engagers in SCLC","volume":"15","author":"Wang","year":"2026","journal-title":"Antibodies"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for patients with previously treated small-cell lung cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a first-in-class DLL3-targeted bispecific T-cell engager, in recurrent small-cell lung cancer: an open-label, phase I study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00553","article-title":"Sustained clinical benefit and intracranial activity of tarlatamab in previously treated small cell lung cancer: DeLLphi-300 trial update","volume":"42","author":"Dowlati","year":"2024","journal-title":"J Clin Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"8015","DOI":"10.1200\/JCO.2024.42.16_suppl.8015","article-title":"DeLLphi-301: Tarlatamab phase 2 trial in small cell lung cancer (SCLC)\u2014efficacy and safety analyzed by presence of brain metastasis","volume":"42","author":"Dingemans","year":"2024","journal-title":"J Clin Oncol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-025-00372-0","article-title":"Asian subgroup analysis of patients in the phase 2 DeLLphi-301 study of tarlatamab for previously treated small cell lung cancer","volume":"13","author":"Ahn","year":"2025","journal-title":"Oncol Ther"},{"key":"B42","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41698-025-00901-0","article-title":"Immunotherapy in lung cancer brain metastases","volume":"9","author":"Paisana","year":"2025","journal-title":"NPJ Precis Oncol"},{"key":"B43","doi-asserted-by":"publisher","first-page":"LBA8008","DOI":"10.1200\/JCO.2025.43.17_suppl.LBA8008","article-title":"Tarlatamab versus chemotherapy (CTx) as second-line (2L) treatment for small cell lung cancer (SCLC): primary analysis of Ph3 DeLLphi-304","volume":"43","author":"Rudin","year":"2025","journal-title":"J Clin Oncol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502099","article-title":"Tarlatamab in small-cell lung cancer after platinum-based chemotherapy","volume":"393","author":"Mountzios","year":"2025","journal-title":"N Engl J Med"},{"key":"B45","unstructured":"FDA\n          FDA grants traditional approval to tarlatamab-dlle for extensive stage small cell lung cancer\n          \n          2025"},{"key":"B46","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.cllc.2025.03.006","article-title":"Real-world outcomes of tarlatamab in small cell lung cancer, including patients with untreated brain metastases","volume":"26","author":"Bolte","year":"2025","journal-title":"Clin Lung Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00480-2","article-title":"Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study","volume":"26","author":"Paulson","year":"2025","journal-title":"Lancet Oncol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70179","article-title":"Tarlatamab plus anti-PD-L1 as first-line maintenance for ES-SCLC demonstrates promising results","volume":"132","author":"Lawrence","year":"2026","journal-title":"Cancer"},{"key":"B49","unstructured":"A phase 3, open-label, multicenter, randomized study of tarlatamab in combination with durvalumab vs durvalumab alone in subjects with extensive-stage small-cell lung cancer following platinum, etoposide and durvalumab (DeLLphi-305)\n          \n          \n          Clinicaltrials.Gov\n          \n          2025"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00363","article-title":"Phase I dose-escalation results for the delta-like ligand 3\/CD3 IgG-like T-cell engager Obrixtamig (BI 764532) in patients with delta-like ligand 3+ small cell lung cancer or neuroendocrine carcinomas","volume":"43","author":"Wermke","year":"2025","journal-title":"J Clin Oncol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-23-0524","article-title":"HPN328, a trispecific T cell-activating protein construct targeting DLL3-expressing solid tumors","volume":"23","author":"Molloy","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"B52","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1200\/JCO.2024.42.4_suppl.121","article-title":"Interim results from a phase 1\/2 study of HPN328, a tri-specific, half-life (T1\/2) extended DLL3-targeting T-cell engager, in patients (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN)","volume":"42","author":"Beltran","year":"2024","journal-title":"J Clin Oncol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1200\/JCO.2026.44.7_suppl.182","article-title":"Efficacy and safety of the DLL3 T-cell engager gocatamig in participants (pts) with neuroendocrine prostate cancer (NEPC) and other neuroendocrine neoplasms (NEN)","volume":"44","author":"Beltran","year":"2026","journal-title":"J Clin Oncol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24129855","article-title":"Current indications and future landscape of bispecific antibodies for the treatment of lung cancer","volume":"24","author":"Arasanz","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1097\/CM9.0000000000002460","article-title":"Current status and future perspectives of bispecific antibodies in the treatment of lung cancer","volume":"136","author":"Wang","year":"2023","journal-title":"Chin Med J (Engl)"},{"key":"B56","unstructured":"ApexOnco\n          Takeda says no to B7-H3\n          \n          2025"},{"key":"B57","unstructured":"Vir biotechnology announces first patient dosed in phase 1 clinical trial of EGFR-targeting PRO-XTEN\u2122 Dual-masked T-cell engager VIR-5525 for the treatment of solid tumors\n          \n          \n          \n          2025"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1583044","article-title":"Mechanistic insights into resistance mechanisms to T cell engagers","volume":"16","author":"Cao","year":"2025","journal-title":"Front Immunol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.3390\/biology15040356","article-title":"Overcoming immunotherapy resistance in small-cell lung cancer","volume":"15","author":"Canale","year":"2026","journal-title":"Biology"},{"key":"B60","unstructured":"Zai lab announces global clinical trial collaboration and supply agreement to evaluate novel DLL3 ADC, zocilurtatug pelitecan, in combination with a bispecific T-cell engager therapy\n          \n          \n          \n          2026"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1476365","article-title":"Prognostic implications of tumor-infiltrating lymphocytes in non-small cell lung cancer: a systematic review and meta-analysis","volume":"15","author":"Yan","year":"2024","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1080\/0284186X.2023.2228991","article-title":"Tumor-infiltrating lymphocytes predict efficacy of immunotherapy in advanced non-small cell lung cancer: a single-center retrospective cohort study","volume":"62","author":"Zhang","year":"2023","journal-title":"Acta Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03752-4","article-title":"Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers","volume":"596","author":"Caushi","year":"2021","journal-title":"Nature"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01462-y","article-title":"Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial","volume":"27","author":"Creelan","year":"2021","journal-title":"Nat Med"},{"key":"B65","doi-asserted-by":"publisher","first-page":"A1718","DOI":"10.1136\/jitc-2024-SITC2024.1488","article-title":"A multicenter phase 2 trial of lifileucel plus pembrolizumab in patients with checkpoint inhibitor-naive metastatic NSCLC: updated results","volume":"12","author":"Creelan","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202409356","article-title":"TIL therapy in lung cancer: current progress and perspectives","volume":"11","author":"Hu","year":"2024","journal-title":"Adv Sci"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1126\/science.1076514","article-title":"Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes","volume":"298","author":"Dudley","year":"2002","journal-title":"Science"},{"key":"B68","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/nrc2355","article-title":"Adoptive cell transfer: a clinical path to effective cancer immunotherapy","volume":"8","author":"Rosenberg","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"B69","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1007\/s00262-024-03793-4","article-title":"Recent clinical researches and technological development in TIL therapy","volume":"73","author":"Matsueda","year":"2024","journal-title":"Cancer Immunol Immunother CII"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200307000-00005","article-title":"Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients","volume":"26","author":"Dudley","year":"2003","journal-title":"J Immunother Hagerstown Md 1997"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003082","article-title":"Combined IL-2, agonistic CD3 and 4-1BB stimulation preserve clonotype hierarchy in propagated non-small cell lung cancer tumor-infiltrating lymphocytes","volume":"10","author":"Shah","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217281","article-title":"Therapeutic potential of tumor-infiltrating lymphocytes in non-small cell lung cancer","volume":"605","author":"Plaugher","year":"2024","journal-title":"Cancer Lett"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2024.11.014","article-title":"Tumor-infiltrating lymphocyte therapy: a new frontier","volume":"31","author":"Tseng","year":"2025","journal-title":"Transplant Cell Ther Off Publ Am Soc Transplant Cell Ther"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00765","article-title":"Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte cell therapy in patients with advanced melanoma: a 5-year analysis of the C-144-01 study","volume":"43","author":"Medina","year":"2025","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-0880","article-title":"FDA approval summary: Lifileucel for unresectable or metastatic melanoma previously treated with an anti-PD-1 based immunotherapy","volume":"31","author":"Hu","year":"2025","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2722","article-title":"A phase II study of tumor-infiltrating lymphocyte therapy for human papillomavirus-associated epithelial cancers","volume":"25","author":"Stevanovi\u0107","year":"2019","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-1334","article-title":"Lifileucel, an autologous tumor-infiltrating lymphocyte monotherapy, in patients with advanced non-small cell lung cancer resistant to immune checkpoint inhibitors","volume":"14","author":"Schoenfeld","year":"2024","journal-title":"Cancer Discov"},{"key":"B79","unstructured":"Interim phase 2 IOV-LUNG-202 data show lifileucel\u2019s potential treating advanced NSCLC | Pharmacy times\n          \n          \n          \n          2026"},{"key":"B80","unstructured":"A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer. [Clinical trial registration]. clinicaltrials.gov\n          \n          \n          \n          2025"},{"key":"B81","doi-asserted-by":"publisher","first-page":"S155","DOI":"10.1016\/j.jtho.2023.09.225","article-title":"Multicenter phase II trial of LN-145 TIL cell therapy plus pembrolizumab in patients with ICI-na\u00efve metastatic NSCLC","volume":"18","author":"Schoenfeld","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1601773","article-title":"Tumor-infiltrating lymphocytes in cancer immunotherapy: from chemotactic recruitment to translational modeling","volume":"16","author":"Kraja","year":"2025","journal-title":"Front Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat Rev Clin Oncol"},{"key":"B84","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N Engl J Med"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2023.09.021","article-title":"Arming CAR-T cells with cytokines and more: innovations in the fourth-generation CAR-T development","volume":"31","author":"Tang","year":"2023","journal-title":"Mol Ther"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1698442","article-title":"Engineering the next generation of CAR T- cells: precision modifications, logic gates and universal strategies to overcome exhaustion and tumor resistance","volume":"15","author":"Garcia-Robledo","year":"2025","journal-title":"Front Oncol"},{"key":"B87","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1186\/s13046-025-03519-z","article-title":"Immunotherapy resistance in non-small cell lung cancer: from mechanisms to therapeutic opportunities","volume":"44","author":"Wang","year":"2025","journal-title":"J Exp Clin Cancer Res CR"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.903562","article-title":"Utility and drawbacks of chimeric antigen receptor T cell (CAR-T) therapy in lung cancer","volume":"13","author":"Kandra","year":"2022","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","first-page":"8579","DOI":"10.1200\/JCO.2026.44.16_suppl.8579","article-title":"Initial safety and efficacy of A2B694, a logic-gated mesothelin-targeted Tmod chimeric antigen receptor T-cell therapy in patients with advanced solid tumors with HLA-A*02 loss of heterozygosity","volume":"44","author":"Molina","year":"2026","journal-title":"J Clin Oncol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-021-03613-7","article-title":"Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed\/refractory non-small cell lung cancer patients","volume":"147","author":"Zhang","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"key":"B91","unstructured":"A Single-arm, Open-label, Phase I Study to Evaluate the Safety and Efficacy of CXCR5 Modified EGFR Chimeric Antigen Receptor Autologous T Cells in EGFR-positive Patients With Advanced Non-small Cell Lung Cancer. [Clinical trial registration]. clinicaltrials.gov\n          \n          \n          \n          2024"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with Malignant pleural disease, in combination with the anti\u2013PD-1 agent pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202508754","article-title":"Anti-PD-1 nanobody-armored MSLN CAR-T therapy for Malignant mesothelioma: preclinical and clinical studies","author":"Sun","year":"2025","journal-title":"Adv Sci"},{"key":"B94","unstructured":"A Phase I Study to Assess the Safety and Antitumor Activity of Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease. [Clinical trial registration]. clinicaltrials.gov\n          \n          \n          \n          2026"},{"key":"B95","doi-asserted-by":"publisher","first-page":"TPS8576","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS8576","article-title":"Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed\/refractory small cell lung cancer (SCLC)","volume":"37","author":"Byers","year":"2019","journal-title":"J Clin Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e20561","article-title":"A systematic review of CAR T-cell therapy in lung cancer: move forward or move on","volume":"43","author":"Ma","year":"2025","journal-title":"J Clin Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1284722","article-title":"PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells","volume":"6","author":"Wei","year":"2017","journal-title":"Oncoimmunology"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00128","article-title":"CAR T cells for solid tumors: new strategies for finding, infiltrating, and surviving in the tumor microenvironment","volume":"10","author":"Martinez","year":"2019","journal-title":"Front Immunol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor antigen escape from CAR T-cell therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-19-0945","article-title":"Tuning the antigen density requirement for CAR T-cell activity","volume":"10","author":"Majzner","year":"2020","journal-title":"Cancer Discov"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838","article-title":"4-1BB costimulation ameliorates T cell exhaustion induced by tonic signaling of chimeric antigen receptors","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0840-5","article-title":"Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer","volume":"26","author":"Lu","year":"2020","journal-title":"Nat Med"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.124144","article-title":"Precision reprogramming in CAR-T cell therapy: Innovations, challenges, and future directions of advanced gene editing","volume":"21","author":"Jia","year":"2025","journal-title":"Int J Biol Sci"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2022.100543","article-title":"Harnessing the chemokine system to home CAR-T cells into solid tumors","volume":"3","author":"Foeng","year":"2022","journal-title":"Cell Rep Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf9419","article-title":"Tertiary lymphoid structures in cancer","volume":"375","author":"Schumacher","year":"2022","journal-title":"Science"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00379","article-title":"Chemokines and chemokine receptors: New targets for cancer immunotherapy","volume":"10","author":"Mollica Poeta","year":"2019","journal-title":"Front Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1609658","article-title":"Membrane-bound IL-15 co-expression powers a potent and persistent CD70-targeted TRuC T-cell therapy","volume":"16","author":"Webb","year":"2025","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.133977","article-title":"TGF-\u03b2 inhibition via CRISPR promotes the long-term efficacy of CAR T cells against solid tumors","volume":"5","author":"Tang","year":"2020","journal-title":"JCI Insight"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"8517","DOI":"10.1200\/JCO.2025.43.16_suppl.8517","article-title":"Hypoxia-responsive CEA CAR-T cells therapy for relapsed or refractory non-small cell lung cancer: A single-arm, open-label, phase I trial","volume":"43","author":"Wei","year":"2025","journal-title":"J Clin Oncol"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.108036","article-title":"From molecular design to clinical translation: Dual-targeted CAR-T strategies in cancer immunotherapy","volume":"21","author":"Wang","year":"2025","journal-title":"Int J Biol Sci"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0051-2","article-title":"Off-the-shelf\u201d allogeneic CAR T cells: Development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2025.09.044","article-title":"Under the hood: Evidence-based review of allogeneic chimeric antigen receptor T cells for hematologic Malignancies","volume":"32","author":"Cheema","year":"2026","journal-title":"Transplant Cell Ther"},{"key":"B115","doi-asserted-by":"publisher","first-page":"4508","DOI":"10.1200\/JCO.2025.43.16_suppl.4508","article-title":"ALLO-316 in advanced clear cell renal cell carcinoma (ccRCC): Updated results from the phase 1 TRAVERSE study","volume":"43","author":"Srour","year":"2025","journal-title":"J Clin Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adf3700","article-title":"TCR-engineered T cell therapy in solid tumors: State of the art and perspectives","volume":"9","author":"Baulu","year":"2023","journal-title":"Sci Adv"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3724\/abbs.2024034","article-title":"The recent advancement of TCR-T cell therapies for cancer treatment","volume":"56","author":"Zhao","year":"2024","journal-title":"Acta Biochim Biophys Sin"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129003","article-title":"Cancer regression in patients after transfer of genetically engineered lymphocytes","volume":"314","author":"Morgan","year":"2006","journal-title":"Science"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-2025-882","article-title":"T cell receptor (TCR)-based therapy in advanced non-small cell lung cancer: A new hope","volume":"14","author":"Costantini","year":"2025","journal-title":"Transl Lung Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","first-page":"197ra103","DOI":"10.1126\/scitranslmed.3006034","article-title":"Identification of a titin-derived HLA-A1\u2013presented peptide as a cross-reactive target for engineered MAGE A3\u2013directed T cells","volume":"5","author":"Cameron","year":"2013","journal-title":"Sci Transl Med"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00319-2","article-title":"SPEARHEAD-1: A single-arm phase 2 trial of afamitresgene autoleucel (afami-cel) in advanced synovial sarcoma and myxoid\/round cell liposarcoma","volume":"403","author":"D\u2019Angelo","year":"2024","journal-title":"Lancet Lond Engl"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003581","article-title":"Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer","volume":"10","author":"Blumenschein","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3910","article-title":"NY-ESO-1 specific TCR engineered T-cells mediate sustained antigen-specific antitumor effects in myeloma","volume":"21","author":"Rapoport","year":"2015","journal-title":"Nat Med"},{"key":"B124","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s40364-023-00534-0","article-title":"Neoantigen-targeted TCR-engineered T cell immunotherapy: Current advances and challenges","volume":"11","author":"Pang","year":"2023","journal-title":"biomark Res"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2025.07.001","article-title":"Neoantigen identification and TCR-T therapy development for solid tumors: Current advances and future perspectives","volume":"5","author":"Zheng","year":"2025","journal-title":"J Natl Cancer Cent"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-025-02252-1","article-title":"TCR-engineered T cells targeting a shared \u03b2-catenin mutation eradicate solid tumors","volume":"26","author":"Eggeb\u00f8","year":"2025","journal-title":"Nat Immunol"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2119662","article-title":"Neoantigen T-cell receptor gene therapy in pancreatic cancer","volume":"386","author":"Leidner","year":"2022","journal-title":"N Engl J Med"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-0070","article-title":"Safety and tolerability of lete-cel in NSCLC-reply","volume":"31","author":"Altan","year":"2025","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"B129","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017414","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0057","article-title":"NCCN Guidelines\u00ae Insights: Management of immunotherapy-related toxicities, Version 2.2024","volume":"22","author":"Thompson","year":"2024","journal-title":"J Natl Compr Cancer Netw JNCCN"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK-25-473916","article-title":"Easy as ABC: Managing toxicities of antibody-drug conjugates, bispecific antibodies, and CAR T-cell therapies","volume":"45","author":"Jain","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35738","article-title":"Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3\u2013targeted bispecific T-cell engager immunotherapy, for previously treated small cell lung cancer","volume":"131","author":"Sands","year":"2025","journal-title":"Cancer"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-24-2247","article-title":"Clinical pharmacology of cytokine release syndrome with T-cell\u2013engaging bispecific antibodies: Current insights and drug development strategies","volume":"31","author":"Radtke","year":"2025","journal-title":"Clin Cancer Res"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07300-8","article-title":"FOXO1 is a master regulator of memory programming in CAR T cells","volume":"629","author":"Doan","year":"2024","journal-title":"Nature"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01751-9","article-title":"New frontiers in immune checkpoint B7-H3 (CD276) research and drug development","volume":"22","author":"Getu","year":"2023","journal-title":"Mol Cancer"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-02142","article-title":"Ifinatamab deruxtecan in patients with extensive-stage small cell lung cancer: Primary analysis of the phase II IDeate-Lung01 trial","volume":"44","author":"Rudin","year":"2026","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2565995","article-title":"IDeate-Lung02: A phase 3 study of second-line ifinatamab deruxtecan in patients with relapsed small cell lung cancer","volume":"21","author":"Owonikoko","year":"2025","journal-title":"Future Oncol"},{"key":"B143","doi-asserted-by":"publisher","first-page":"S1074","DOI":"10.1016\/j.annonc.2024.08.1903","article-title":"IDeate-Lung03: A phase Ib\/II study of ifinatamab deruxtecan (I-DXd) plus atezolizumab (atezo) with or without carboplatin (carbo) as first-line (1L) induction or maintenance in patients (pts) with extensive stage (ES) small cell lung cancer (SCLC)","volume":"35","author":"Rudin","year":"2024","journal-title":"Ann Oncol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1390006","article-title":"Advances in CAR-NK cell therapy for lung cancer: Is it a better choice in the future","volume":"14","author":"Liu","year":"2024","journal-title":"Front Oncol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01829","article-title":"Harnessing the power of invariant natural killer T cells in cancer immunotherapy","volume":"8","author":"Bedard","year":"2017","journal-title":"Front Immunol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.abd6971","article-title":"Weighting tumor-specific TCR repertoires as a classifier to stratify the immunotherapy delivery in non\u2013small cell lung cancers","volume":"7","author":"Han","year":"2021","journal-title":"Sci Adv"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1038\/nature22364","article-title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","volume":"545","author":"Abbosh","year":"2017","journal-title":"Nature"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3390\/jcm14196960","article-title":"Update on the treatment of non-small cell lung carcinoma (NSCLC)","volume":"14","author":"Kariri","year":"2025","journal-title":"J Clin Med"},{"key":"B149","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s40164-025-00720-w","article-title":"Immunotherapy for small cell lung cancer: Current challenges and prospects","volume":"14","author":"Zhong","year":"2025","journal-title":"Exp Hematol Oncol"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines13020128","article-title":"Emerging immunotherapies for advanced non-small-cell lung cancer","volume":"13","author":"Wolf","year":"2025","journal-title":"Vaccines"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1917770\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T06:43:46Z","timestamp":1788417826000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1917770\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,3]]},"references-count":150,"alternative-id":["10.3389\/fimmu.2026.1917770"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1917770","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,3]]},"article-number":"1917770"}}